Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.30
Bid: 0.301
Ask: 0.32
Change: -0.0105 (-3.38%)
Spread: 0.019 (6.312%)
Open: 0.30
High: 0.30
Low: 0.30
Prev. Close: 0.3105
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

23 Nov 2015 07:00

RNS Number : 5404G
Integrated Diagnostics Holdings PLC
23 November 2015
 



 

Integrated Diagnostics Holdings PLCReports Update on 9M 2015 Results

 

 

 

EGP 745 mn

in total sales

19%

45%

normalized EBITDA margin

2pps

17.2 mn

tests completed7%

4.3 mn

patients served6%

  

All comparisons are versus 9M2014

 

Jersey, 23 November 2015

 

Integrated Diagnostics Holdings PLC ('IDH'), IDHC on the London Stock Exchange, Egypt's largest fully integrated private-sector provider of medical diagnostics services, released today unaudited highlights of its financial and operational performance in the first nine months of 2015, reporting a 19% rise in total unaudited revenues to EGP 745 million.

 

As per management accounts, the company reported an unaudited, normalised EBITDA margin of 45% in 9M2015, up two percentage points from the same period in 2014.

 

"By the terms regulating the company's listing on the LSE, IDH is required to release audited financials only at the half- and full-year marks. Management and the Board of Directors have committed to providing performance updates in the first and third quarters as an outgrowth of our commitment to transparency," said Chief Executive Officer Dr. Hend El-Sherbini.

 

"Against this backdrop, I am very pleased to report that we continue to execute on target according to our previously communicated guidance. We have fully moved into our new central Megalab facility and opened eight new 'C' labs in the third quarter, bringing our total network to 308 as of 30 September 2015," said El-Sherbini.

 

The Megalab is a key component of the company's growth strategy going forward. It will permit the widening and deepening of the Group's footprint through the rollout of new, capital-efficient 'C' labs (primarily collection centres in areas convenient to clients); allow the pursuit of new business by taking on outsourced work for hospitals and third-party labs; facilitate regional expansion; and see IDH introduce more esoteric tests. Management is presently preparing to secure CAP (College of American Pathologists) accreditation for the Megalab.

 

"Heading into the final quarter of the year, we are fully focused on operations as we continue to roll out our proven 'hub, spoke and spike' strategy in a very exciting, fragmented and under-served market," concluded El-Sherbini. "Egypt is an exceptionally exciting market, and we look forward to creating superior shareholder value by focusing on the long-term."

 

 

 

-Ends-

 

 

 

 

About Integrated Diagnostics Holdings (IDH)

IDH is the largest fully integrated private-sector medical diagnostics services provider in Egypt, comprehensively offering pathology, molecular diagnostics, surgical pathology, genetic testing and basic radiology. IDH's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) the and Medical Genetics Centre, both of which operate in Egypt. IDH is listed on the London Stock Exchange (ticker: IDHC) and was founded in 2012 by the merger of Al Borg and Al Mokhtabar, the most established diagnostics services brands in Egypt. Learn more at idhcorp.com.

 

 

Shareholder Information

LSE: IDHC.L

Bloomberg: IDHC:LN

Listed: May 2015

Shares Outstanding: 150 million

 

 

Contact

Mr. Sherif El-Ghamrawi

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)10 0447 8699 | sherif.elghamrawi@idhcorp.com

 

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each case their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding business and management, future growth or profitability and general economic and regulatory conditions and other matters affecting the Company.

 

Forward-looking statements reflect the current views of the Company's management ("Management") on future events, which are based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause the Company's actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements.

 

The Company's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate or prediction to differ materially from those expressed or implied by the forward-looking statements contained in this prospectus. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMZMDZVGKZM
Date   Source Headline
5th Aug 20223:27 pmRNSDirector/PDMR Shareholding
4th Aug 20224:09 pmRNSDirector/PDMR Shareholding
3rd Aug 20226:01 pmRNSDirector/PDMR Shareholding
3rd Aug 20224:16 pmRNSDirector/PDMR Shareholding
2nd Aug 202210:43 amRNSDirector/PDMR Shareholding
27th Jul 20229:59 amRNSFinal Dividend Distribution
8th Jun 20228:45 amRNS1st Quarter Results
8th Jun 20227:00 amRNSResult of AGM
1st Jun 20225:39 pmRNSNotice of Results
23rd May 20224:35 pmRNSPrice Monitoring Extension
12th May 20225:37 pmRNSAnnual Financial Report & Notice of AGM
21st Apr 20229:46 amRNSPreliminary Results
31st Mar 202210:04 amRNSIFC and IFC MENA Fund acquire 5% stake in IDH
29th Mar 20228:30 amRNSIDH launches fifth Al-Borg Scan Branch
1st Mar 20222:00 pmRNSDirectorate Change
20th Dec 202110:26 amRNSReplacement: IDH 50% Acquisition of IDC
20th Dec 20218:00 amRNSIDH Acquisition of Islamabad Diagnostic Centre
16th Nov 20217:00 amRNS3rd Quarter Results
12th Nov 202112:03 pmRNSNotice of Results
28th Oct 20214:34 pmRNSNotice of Arbitration
4th Oct 202111:48 amRNSIDH launches third Al-Borg Scan branch
24th Sep 202112:50 pmRNSIDH 1H 2021 Standalone Financial Statements
2nd Sep 20217:00 amRNSHalf-year Report
18th Aug 202110:04 amRNSBiolab to operate testing stations in QAIA
9th Jul 20214:16 pmRNSFinal dividend clarification
30th Jun 202112:21 pmRNSResult of AGM
17th Jun 202110:02 amRNSFinal Dividend Resolution – Date Amendments
7th Jun 20215:24 pmRNSAnnual Financial Report & Notice of AGM
7th Jun 20217:00 amRNSChange of Auditor
2nd Jun 20217:00 amRNS1st Quarter Results
27th May 20215:07 pmRNSShare Transfer Mechanism and Documents
25th May 20217:00 amRNSIDH partners with IFC on USD 45m debt financing
20th May 202111:58 amRNSIDH debuts trading on EGX
19th May 20217:00 amRNSFinal Results
6th May 20216:02 pmRNSFRA dual listing approval
5th May 202110:21 amRNSIDH EGX Dual Listing Approval
22nd Mar 202112:31 pmRNSDual Listing - FRA registration approval
18th Feb 202112:25 pmRNSTrading update for the year ended 31 December 2020
17th Feb 20214:41 pmRNSSecond Price Monitoring Extn
17th Feb 20214:36 pmRNSPrice Monitoring Extension
15th Jan 20214:36 pmRNSPrice Monitoring Extension
31st Dec 202012:40 pmRNSSecond Price Monitoring Extn
31st Dec 202012:35 pmRNSPrice Monitoring Extension
29th Dec 20204:36 pmRNSPrice Monitoring Extension
23rd Dec 20201:35 pmRNSResults of EGM and Subdivision of Share Capital
4th Dec 20207:00 amRNSNotice of Extraordinary General Meeting
27th Nov 20204:36 pmRNSPrice Monitoring Extension
20th Nov 20204:40 pmRNSSecond Price Monitoring Extn
20th Nov 20204:35 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNS3rd Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.